anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
IMPORTANCE: Obesity affects approximately 21% of US adolescents and is associated with insulin resistance, hypertension, dyslipidemia, sleep disorders, depression, and musculoskeletal problems. Obesity during adolescence has also been associated with an increased risk of mortality from cardiovascular disease and type 2 diabetes in adulthood.
OBSERVATIONS: Obesity in adolescents aged 12 to younger than 18 years is commonly defined as a body mass index (BMI) at the 95th or greater age- and sex-adjusted percentile. Comprehensive treatment in adolescents includes lifestyle modification therapy, pharmacotherapy, and metabolic and bariatric surgery. Lifestyle modification therapy, which includes dietary, physical activity, and behavioral counseling, is first-line treatment; as monotherapy, lifestyle modification requires more than 26 contact hours over 1 year to elicit approximately 3% mean BMI reduction. Newer antiobesity medications, such as liraglutide, semaglutide, and phentermine/topiramate, in combination with lifestyle modification therapy, can reduce mean BMI by approximately 5% to 17% at 1 year of treatment. Adverse effects vary, but severe adverse events from these newer antiobesity medications are rare. Surgery (Roux-en-Y gastric bypass and vertical sleeve gastrectomy) for severe adolescent obesity (BMI ≥120% of the 95th percentile) reduces mean BMI by approximately 30% at 1 year. Minor and major perioperative complications, such as reoperation and hospital readmission for dehydration, are experienced by approximately 15% and 8% of patients, respectively. Determining the long-term durability of all obesity treatments warrants future research.
CONCLUSIONS AND RELEVANCE: The prevalence of adolescent obesity is approximately 21% in the US. Treatment options for adolescents with obesity include lifestyle modification therapy, pharmacotherapy, and metabolic and bariatric surgery. Intensive lifestyle modification therapy reduces BMI by approximately 3% while pharmacotherapy added to lifestyle modification therapy can attain BMI reductions ranging from 5% to 17%. Surgery is the most effective intervention for adolescents with severe obesity and has been shown to achieve BMI reduction of approximately 30%.
The mobile platform is used to evaluate the nutrition of patients 2 weeks after the first course of induction chemotherapy, before radiotherapy, during radiotherapy, after radiotherapy, and 1 month after radiotherapy. The doctor pushes individualized nutrition education, oral advice, medication advice, etc. .
The abundant genetic variation harbored by wild rice (Oryza rufipogon) has provided a reservoir of useful genes for rice breeding. However, the genome of wild rice has not yet been comprehensively assessed. Here, we report the haplotype-resolved gapless genome assembly and annotation of wild rice Y476. In addition, we develop two sets of chromosome segment substitution lines (CSSLs) using Y476 as the donor parent and cultivated rice as the recurrent parents. By analyzing the gapless reference genome and CSSL population, we identify 254 QTLs associated with agronomic traits, biotic and abiotic stresses. We clone a receptor-like kinase gene associated with rice blast resistance and confirm its wild rice allele improves rice blast resistance. Collectively, our study provides a haplotype-resolved gapless reference genome and demonstrates a highly efficient platform for gene identification from wild rice.
Participants will undergo a conventional upper extremity rehabilitation program for 45 minutes a day, 5 days a week, for 6 weeks. In addition to the conventional rehabilitation program, dual-task training will be provided with a 30-minute virtual reality training program. Cognitive tasks will be given in addition to virtual reality training as dual-task training.
Capsules of gelatine or the like containing medical or pharmaceutical substances are protected by one or more layers of a non-cellulosic substance, e.g. sugar or talc, and have interposed between the protective layer and the gelatine an insulating layer of a non-enteric cellulose compound, e.g. collodion, which may also serve as an adhesive for the protective layer.  Insulating layers may be interposed between successive protective layers. The protective layer may be applied by means of an aqueous solution of an adhesive, e.g. sugar syrup or gum acacia, or the capsules may be dipped into a solution of the protective substance and then dried, or coating may be carried out in an open rotary drum, the axis of which is arranged obliquely.  The protective coating may consist of an enteric substance, e.g. shellac or keratin.  According to the Provisional Specification, the protective coating may be of pearl, and is not limited to non-cellulose substances.  Also the intermediate coating is not limited to non-enteric cellulose compounds, and reference is made to the use of varnish.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Amlodipine has been evaluated for safety in more than 11,000 patients in U.S. and foreign clinical trials. In general, treatment with amlodipine was well-tolerated at doses up to 10 mg daily. Most adverse reactions reported during therapy with amlodipine were of mild or moderate severity. In controlled clinical trials directly comparing amlodipine (N=1730) at doses up to 10 mg to placebo (N=1250), discontinuation of amlodipine because of adverse reactions was required in about 1.5% of patients and was not different from placebo (about 1%). The most commonly reported adverse reactions more frequent than placebo are reflected in the table below. The incidence (%) of adverse reactions that occurred in a dose related manner are as follows:

Other adverse reactions that were not clearly dose related but were reported with an incidence greater than 1.0% in placebo-controlled clinical trials included the following:

For several adverse experiences that appear to be drug and dose related, there was a greater incidence in women than men associated with amlodipine treatment as shown in the following table:
BACKGROUND: Measures of physical activity and pain-related patient-reported outcomes are important components of patient recovery after surgery. However, little is known about their association in the early post-operative period. This study aims to increase this knowledge. Our primary objective was to determine the association between average pain intensity and activity (in steps) 1 week after surgery. Secondary objectives were the association of activity with other patient-reported outcomes, age, sex, comorbidities and body mass index.
METHODS: Data were obtained from the PROMPT sub-project of IMI-PainCare. Patients after breast and endometriosis-related surgery, sternotomy and total knee arthroplasty completed pain-related outcomes questionnaires and wore an ActiGraph activity-tracking device. We correlated steps with average pain intensity on post-operative days 6 and 7. Secondary analyses were done using correlations and t-tests.
RESULTS: In 284 cases, there was no statistically significant correlation between steps and average pain intensity. In addition, none of the 28 secondary analyses showed a statistically significant result.
CONCLUSIONS: Pain-related patient-reported outcome measures and physical activity are separate entities. Both should be measured after surgery to assess patient recovery and to identify treatment deficiencies.
SIGNIFICANCE STATEMENT: Measuring recovery is a multi-dimensional challenge. After surgery, clinicians need to be aware that neither pain intensity nor activity levels tell the whole story. Each can hint to problems and treatment requirements.
The synovium is an important component of any synovial joint and is the major target tissue of inflammatory arthritis. However, the multi-omics landscape of synovium required for functional inference is absent from large-scale resources. Here we integrate genomics with transcriptomics and chromatin accessibility features of human synovium in up to 245 arthritic patients, to characterize the landscape of genetic regulation on gene expression and the regulatory mechanisms mediating arthritic diseases predisposition. We identify 4765 independent primary and 616 secondary cis-expression quantitative trait loci (cis-eQTLs) in the synovium and find that the eQTLs with multiple independent signals have stronger effects and heritability than single independent eQTLs. Integration of genome-wide association studies (GWASs) and eQTLs identifies 84 arthritis related genes, revealing 38 novel genes which have not been reported by previous studies using eQTL data from the GTEx project or immune cells. We further develop a method called eQTac to identify variants that could affect gene expression by affecting chromatin accessibility and identify 1517 regions with potential regulatory function of chromatin accessibility. Altogether, our study provides a comprehensive synovium multi-omics resource for arthritic diseases and gains new insights into the regulation of gene expression.
A method for preparing the medicine 'Ruhepi powder' for treating mastopathy includes such steps as dissolving the medicine in water, adding the medicine, stirring, and stirring. The pain of the patient is increased, the medical expense of the patient is increased, the time for the patient to go to the hospital for treatment is wasted, and the outpatient service volume of the hospital and the workload of medical care personnel are increased. The method is characterized in that: selecting 30g of safflower, 30g of salvia miltiorrhiza, 30g of green tangerine peel, 30g of szechwan chinaberry fruit, 30g of beautiful sweetgum fruit, 30g of tangerine seed, 30g of white paeony root, 60g of common selfheal fruit-spike, 30g of platycodon root, 30g of figwort root, 30g of pangolin scales, 30g of fritillaria, 30g of lychee seed and 30g of red paeony root. Grinding into powder, sieving with a fine sieve of 80-120 meshes, and mixing. The advantages are that: has obvious treatment effect, good effect and short treatment period, and strives for the optimal treatment time for patients. The pain of the patient is reduced, the medical cost of the patient is reduced, and the outpatient service volume of the hospital and the workload of medical care personnel are reduced. For the treatment of breast diseases.
Intervention: The HH4M patient website will include information and tools. These resources are customized to help new mothers achieve the AHA Class I Lifestyle recommendations for women with a history of preeclampsia.
A preliminary patient and clinician-generated scale will be validated and modified during a multicenter scale validity study involving 85 patients from 5 sites. Feasibility surveys have been conducted and available sites that can be included in this study include Boston Children's/ Harvard, Midwest Immunology, Johns Hopkins, Children's Hospital at Baylor University, and the University of South Florida at All Children's Hospital Johns Hopkins Medicine. Patients will be enrolled at a clinic non-infusion visit. The purpose of the study will be explained and informed consent obtained. A case report form (CRF) of their clinical condition and demographics will be completed based on the information obtained by the local study coordinator during the interview at the time of the visit. The HR-QOL PIDD survey will be administered to the patient by the site PI or the study coordinator. A second survey will be handed to the patient to take home with them and completed at 48-120 hrs. after the clinic visit. The study coordinator will contact the patient during this period to ensure that the patient completes this second survey and returns it to the local study site. If a patient is on SCIg they will be asked to take the survey 3 days after the SC infusion (if weekly), and complete the paired survey 48-72 hrs later (before another SCIg infusion is scheduled). The study coordinator will obtain an interim history for the period between the paired surveys to ensure that, in general, the condition of the patient has not changed that could invalidate the validation process, and this information will be documented on the addendum case report form (CRF). Patient can return the surveys to the site study coordinator either by mail, fax or electronically by scanning the documents. Paired surveys will be returned to the central study site (USF St Petersburg) for data input.
The invention relates to the use of basic amino acids in aqueous hair treatment products, for protecting hair from heat damage. L-histidine is particularly well suited to this purpose, in preparations for shaping and fixing the hair using hot air. The concentration of said basic amino acids in the preparation is preferably 0.01-1 wt. % and they preferably have a pH value of 4.5-7. Preparations for fixing and shaping hair, containing 0.1-5.0 wt. % of a film-forming polymerisate and 0.05-2 wt. % of a basic amino acid in an aqueous or aqueous-alcoholic solution are particularly preferable.
Clinics randomized to the intervention arm will be introduced to the five steps of SAIA by study staff. The cascade analysis will be performed within the FP clinic to identify drop-offs in cervical cancer screening and referrals, using an Excel-based tool adapted from previous SAIA trials. Flow mapping performed by clinic and study staff will describe the cervical cancer screening process including who the client interacts with, timing of these interactions, any cervical cancer screening performed, and any referrals made. Initial drafts will be reviewed together with clinic and study stuff to ensure adequate and complete representations of processes. Study staff will work with clinic staff to identify bottlenecks in the process and potential solutions to improve flow. Proposed solutions will be implemented, and the process will be examined again to determine the effect of the implemented changes. The cycle will be repeated approximately every 6-8 weeks during the RCT.
The present invention relates to a technique for separating antineoplastic components from ganoderma lucidum spores. Ganoderma lucidum spore powder is soaked by organic solvent, extract liquid is separated with a centrifugal method, and oily substances are obtained by decompression and concentration at the temperature of 50 DEG C by rotating an evaporimeter. The latter is separated by the chromatography of a common silica gel column. Elution is orderly carried out by chloroform, ethyl acetate and methanol, one series of cream substances are obtained after the chloroform, and the ethyl acetate and the methanol are respectively evaporated and dried. The toxicity of the cream substances is detected by cervical carcinoma HeLa cells. Natural antineoplastic components can be obtained by the technique, and the yield rate is high. The components have obvious activity during the low concentration of 0.08 mg/ml and have great application values. The present invention has the advantages of simple whole technical process and low cost.
An apparatus, including a computer programmed for facilitating a tele-health visit including a video call and a first electronic healthcare record for an individual. The computer includes a database which stores the first electronic healthcare record. The apparatus facilitates a video call between a user device and a provider device. The provider device records a photograph or video clip of the individual, generates an alert message, and transmits the alert message to the user device. The provider device processes information for updating the first electronic healthcare record. The computer stores information for updating, and stores an update to, the first electronic healthcare record. The computer processes information for updating, and updates, a second electronic healthcare record for the individual or the computer processes information for updating, and updates, an electronic medical record, electronic dental record, electronic pharmacy record, or personal health record, for the individual.
This retrospective cohort study aimed to develop and evaluate a machine-learning algorithm for predicting oliguria, a sign of acute kidney injury (AKI). To this end, electronic health record data from consecutive patients admitted to the intensive care unit (ICU) between 2010 and 2019 were used and oliguria was defined as a urine output of less than 0.5 mL/kg/h. Furthermore, a light-gradient boosting machine was used for model development. Among the 9,241 patients who participated in the study, the proportions of patients with urine output < 0.5 mL/kg/h for 6 h and with AKI during the ICU stay were 27.4% and 30.2%, respectively. The area under the curve (AUC) values provided by the prediction algorithm for the onset of oliguria at 6 h and 72 h using 28 clinically relevant variables were 0.964 (a 95% confidence interval (CI) of 0.963-0.965) and 0.916 (a 95% CI of 0.914-0.918), respectively. The Shapley additive explanation analysis for predicting oliguria at 6 h identified urine values, severity scores, serum creatinine, oxygen partial pressure, fibrinogen/fibrin degradation products, interleukin-6, and peripheral temperature as important variables. Thus, this study demonstrates that a machine-learning algorithm can accurately predict oliguria onset in ICU patients, suggesting the importance of oliguria in the early diagnosis and optimal management of AKI.
NEW MATERIAL:A compound of formulaI(R1, R2 are H, lower alkyl). EXAMPLE:L-Tylosyl-D-methioninesulfoxide-glycil-N-methylphenethylamine. USE:It is used as a medicine such as an analgesic. It has an antiagonistic activity against the opiate receptor. PREPARATION:The reaction of a dipeptide of formula II (A1 is amino-protecting group; A2 is H, hydroxyl protecting group) or its reactive derivative at the carboxyl group such as acid azide, mixed acid anhydride or active ester, with glycylamide derivative gives a compound of formula IV. Then, protecting groups are removed from the product to give the compound of formulaI. The reaction is usually carried out in a solvent such as THF, DMF or chloroform in a temperature range from about -20 deg.C to about 50 deg.C.
BED is a serious condition that is associated with psychiatric comorbidity, psychosocial impairment, and obesity. Interpersonal psychotherapy (IPT), behavioral weight loss (BWL) interventions, and guided self help (GSH) treatments for BED have been evaluated, but the safest and most effective treatment has not yet been identified. This study will determine which of these three treatments is most effective in treating BED.

Participants are stratified by negative affect subtype and are randomly assigned for 6 months to one of three treatment groups: IPT, BWL, or GSH. IPT focuses on current interpersonal problems which are hypothesized to increase negative affect and lead to binge eating. BWL interventions involve the adoption of weight loss inducing behaviors. GSH is a shortened version of cognitive behavioral therapy that focuses directly on eating behavior. IPT and BWL patients have 20 treatment sessions; those receiving GSH have 10 sessions. Assessments are made pre-treatment, post-treatment, and at 6, 12, 18, and 24 months after treatment is complete.
It is believed that the macular pigment protects the retina against photooxidative damage which can lead to agerelated macular degeneration (AMD). It is also hypothesized to enhance visual performance in normal human eyes. Much of the research into lutein supplementation has been centered around AMD subjects. AMD can result from agerelated retinal photoreceptor dysfunction which could hypothetically be prevented or slowed down through early supplementation. To our knowledge, the effects of lutein in normal ageing, have not been studied previously.

Macular pigment is composed of lutein and zeaxanthin. These compounds absorb blue light and therefore protect the retinal photoreceptors. They also possess powerful antioxidant properties and therefore help maintain the integrity of the macular region. With increasing age, the visual performance worsens as a result of preretinal and retinal changes such as photoreceptor degeneration. Rods (responsible for night vision) are highly susceptible to degeneration in a normal aging eye and in AMD. Older subjects often complain of reduced vision in the dark which can contribute to increased risk of road traffic accidents and falls. Since the older population is rapidly growing, it is vital to study the mechanics of photoreceptor degeneration and the possible beneficial effects of supplementation with retinal carotenoids, particularly lutein.

The supplement that will be used in this study will be the commercially available Visionace Plus (details attached). The manufacturer of Visionace Plus is Vitabiotics. The placebo will be soya-based, also manufactured by Vitabiotics.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a progressive disease leading to paralysis. CIDP is an immune-mediated disorder resulting from a synergistic interaction of T cell-mediated and B cell-mediated immune responses directed against peripheral nerve antigens. These immune mediated responses in turn increase the production of reactive oxygen intermediate and cause oxidative damage of the peripheral nerve system. Although corticosteroids, plasma exchange, and intravenous immunoglobulin (IVIg) reduce impairment caused by CIDP at least temporarily and can be used as a first-line treatments, they are not ideal for long-term treatment because of serious side effects and cost. Alpha lipoic acid (LA) is an antioxidant that also possesses anti-immune activity. It is effective in treating diabetic neuropathy. It is also promising in treating patients with multiple sclerosis.
Vorinostat by mouth two times (2X) per day for two weeks followed by one week of rest. Rituximab intravenously once every three weeks .
PURPOSE:To obtain an antifungal agent for external use, containing griseofulvin having excellent antifungal action and griseofulvin dissolvent, e.g. benzyl nicotinate, etc., as an active ingredient and having high percutaneous absorbability without side effects. CONSTITUTION:An antifungal agent for external use obtained by containing griseofulvin expressed by the formula and one or two or more griseofulvin dissolvents selected from the group consisting of benzyl nicotinate, ethyl nicotinate, menthol, camphor, methyl salicylate, glycol salicylate, crotamiton, diphenhydramine and benzyl alcohol as an active ingredient. The griseofulvin is preferably blended in an amount of 0.01-20wt% and the minimum amount required of the griseofulvin dissolvents is 5-30pts.wt. based on 1pts.wt. griseofulvin. An absorption adjuvant, e.g. dimethyl sulfoxide, etc., can be contained in addition to the above-mentioned active ingredient.
NEW MATERIAL:(7S)-8-Hydroxy-3,7-dimethyl-10-(1-methyl ethylidene)-5-cyclodecene-1-one. USE:A medicine such as anti-inflammatory agent. PREPARATION:Curcuma zedoaria R. is dipped in an organic solvent and the extracted liquid is concentrated and then the resultant extract is fractionated using a column chromatography and high-performance liquid chromatography and the fractionated material is crystallized from an organic solvent. Then cerium chloride and reducing agent such as sodium borohydride are added to a solution of organic solvent (e.g. methanol) of the resultant crystal and the mixture is stirred. Then the reduced product is extracted with an organic solvent such as ethyl acetate and then the extract is separated and purified using a column chromatography to provide the terpene derivative expressed by the formula.